Asset profile

insulin glargine · Lantus / Toujeo

Peptide

Approvedregulatory verdict

Evidence outlook

Approved — Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (2)
January 2027 (1)
Phase 1/2Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-01-01 · NCT07757464 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 2Alzheimer Disease, Mild Cognitive Impairment, Metabolic SyndromeRecruiting
Est. primary completion 2027-12-01 · NCT06072963 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (2)
April 2028 (1)
Phase 2Alzheimer DiseaseNot yet recruiting
Est. primary completion 2028-04 · NCT07756294 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2028 (1)
Phase 1/2Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation GlaucomaNot yet recruiting
Est. primary completion 2028-10 · NCT07619482 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
May 2029 (1)
Phase 2/3Type 2 DiabetesRecruiting
Est. primary completion 2029-05-18 · NCT07675499 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2030 (1)
April 2030 (1)
Phase 2Type 2 DiabetesNot yet recruiting
Est. primary completion 2030-04 · NCT07421518 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.